Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TURQUOISE-I
2012-005143-24Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2015
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ombitasvir, paritaprevir, ritonavir, dasabuvir, ribavirin in hepatitis C virus infection, Human immunodeficiency virus infection type 1, sponsored by AbbVie Inc.. Started Apr 2015; status: completed.
02
Drugs
ombitasvirparitaprevirritonavirdasabuvirribavirin
03
Conditions
hepatitis C virus infectionHuman immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2012-005143-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005143-24.